About Editorial team of BIPNs

Main team of content of bipns.com. Any type of content should be approved by us.
31 07, 2025

Super Speciosa Reinforces Safety Leadership in Kratom

By |2025-07-31T23:45:15+03:00July 31, 2025|Dietary Supplements News, News|0 Comments


Jacksonville, July 31, 2025 (GLOBE NEWSWIRE) —

Kratom Industry Under Fire — But One Brand Stands Above the Rest

In mid-July 2025, the U.S. Food and Drug Administration (FDA) issued a series of warning letters to companies found marketing kratom products containing concentrated levels of the alkaloid 7-hydroxymitragynine (7-OH). These synthetic or enhanced formulations—often promoted as shots, gummies, or fast-acting tablets—were deemed unapproved drugs and adulterated supplements by federal regulators. The crackdown sent a ripple through the kratom industry and sparked growing anxiety among consumers seeking trustworthy kratom options in an increasingly scrutinized market.

While the FDA’s enforcement efforts focused on products that contained added or isolated 7-OH—an alkaloid naturally found in kratom in trace amounts—the broader impact was unmistakable: millions of consumers suddenly began to reevaluate who they were buying from.

In that moment of public confusion, one brand stood out not just as a supplier—but as a long-standing leader in kratom safety, compliance, and customer trust: Super Speciosa.

Explore Super Speciosa’s Full Product Line

What Makes Super Speciosa Different?

In a marketplace often defined by inconsistency, Super Speciosa stands apart for one simple reason: it never took shortcuts. While many kratom brands entered the scene with minimal quality controls or vague sourcing claims, Super Speciosa built its entire model around something rare in the industry—verifiable trust.

At the heart of the company’s difference is a deep commitment to the natural form of kratom—the leaf, as it grows in Southeast Asia—processed and packaged with precision, without synthetic enhancement or chemical modification. Super Speciosa doesn’t sell “boosted” kratom. It doesn’t isolate alkaloids like 7-hydroxymitragynine (7-OH), nor does it infuse its products with ingredients designed to manipulate the plant’s effects. Instead, it focuses entirely on maintaining the integrity of the leaf as it exists in nature—ensuring that what the customer receives is exactly what kratom is supposed to be.

The company’s track record of compliance leadership began long before 2025. Super Speciosa was one of the first brands in the U.S. to become certified under the American Kratom Association’s Good Manufacturing Practices (GMP) Program. This is not a marketing label—it’s a rigorous operational standard that requires documented safety protocols, clean-room level handling processes, and independent audits to maintain compliance.

Moreover, Super Speciosa follows a pharmaceutical-style chain-of-custody model. Every kratom product they sell can be traced back to a specific batch and set of lab tests. This means that consumers are not just buying a product—they’re buying a verified supply chain. Unlike many vendors who source their kratom from unknown brokers or mix-and-match inventory, Super Speciosa maintains strict relationships with qualified growers and processors. The result is a consistent, replicable product experience that far exceeds what’s typical in the supplement space—let alone in kratom.

The company’s in-house Quality Control team plays a critical role in this process. Every product that ships is matched with its own Certificate of Analysis from an independent third-party lab. These certificates test for microbiological contamination (like salmonella or E. coli), heavy metals (like lead, mercury, or arsenic), and residual solvents or adulterants. These aren’t just formalities—they’re foundational to Super Speciosa’s business model, and they’re part of why the brand has grown into one of the most trusted names in the industry.

In 2025, as the FDA issues warning letters and regulators close in on companies that ignored these standards, Super Speciosa’s model looks not only responsible—but visionary.

See Super Speciosa’s Full Product Line — Lab Tested and GMP-Certified

What the FDA Crackdown Means for Kratom Shoppers

To understand how serious the FDA’s July 2025 enforcement action is, it’s important to look at the substances involved. 7-hydroxymitragynine, or 7-OH, is a naturally occurring alkaloid in kratom, but only in extremely small amounts. The FDA’s concern wasn’t with natural kratom leaf—it was with products that enhance, isolate, or synthetically increase the presence of 7-OH to create more potent, drug-like effects.

Many of the products named in the FDA’s warning letters were advertised with claims about managing pain, easing anxiety, or mimicking opioid withdrawal therapies. These are explicit medical claims, which the FDA classifies as unlawful when made by dietary supplements or unapproved drug formulations.

So what does this mean for the everyday kratom consumer?

It means that unless a brand follows legitimate sourcing, testing, and manufacturing standards, there’s no guarantee about what’s in the product—or whether it’s legal.

See Coverage: Best Kratom for Pain? Top Super Speciosa Review Gets 2025 Buzz

With the rise of synthetic 7-OH products being removed from the marketplace, consumers are now actively searching for brands they can trust. That’s why Super Speciosa’s consistent adherence to GMP, and its open rejection of synthetic enhancement techniques, is resonating across the community.

Super Speciosa’s Safety-First Formula

When it comes to consumer trust in supplements—especially ones as misunderstood and unregulated as kratom—safety isn’t a nice-to-have. It’s a requirement. And at Super Speciosa, safety isn’t just a box to check; it’s a system-wide priority that touches every step of the production cycle, from farm to finished product.

The company starts by sourcing raw kratom leaf material from trusted growers in Southeast Asia, where relationships are built not just on price, but on sustainable harvesting, clean drying practices, and mutual transparency. From the moment the leaf is collected, the clock starts ticking on quality. That’s why Super Speciosa has implemented a pasteurization process upon arrival to the U.S.—a method that uses low, controlled heat to eliminate microbial threats like salmonella, mold, or E. coli, without compromising the plant’s natural alkaloid profile.

This is especially critical in an era where other kratom vendors are cutting corners with chemical solvents, poorly ventilated drying racks, or even cross-contaminated handling equipment. Super Speciosa’s facilities adhere to FDA-style cleanliness standards, including segregated production zones, stainless steel batching equipment, and controlled environment packaging areas. It’s this kind of infrastructure that sets them apart in an industry where many vendors still package powder in backrooms or third-party fulfillment centers with minimal oversight.

But what truly sets Super Speciosa’s safety model apart is their 100% batch-level testing protocol.

Unlike companies that “spot check” a random percentage of their kratom shipments, Super Speciosa samples every single batch—no exceptions. And it’s not just for show. These tests are carried out by independent, ISO-certified third-party laboratories, which provide a full Certificate of Analysis (COA) for each product line. Tests cover microbial load, heavy metals (arsenic, cadmium, lead, mercury), yeast and mold counts, and alkaloid presence (primarily mitragynine and 7-OH at trace levels).

If a batch fails to meet safety specifications, it’s not remediated or blended into another lot—it’s destroyed. This is where the brand’s GMP compliance truly shows: zero tolerance for risk, no matter the financial cost.

Each lab report is tied to a lot number, which is printed clearly on every product package. That means any customer—at any time—can look up their specific batch’s test results. This level of consumer transparency is rare even among larger supplement brands, and it’s one reason why Super Speciosa consistently earns high marks in user reviews and third-party audits alike.

And importantly, Super Speciosa does not isolate or enhance 7-hydroxymitragynine, the alkaloid at the center of the FDA’s July 2025 enforcement action. The company’s products contain only the naturally occurring balance of alkaloids as found in raw kratom leaf, processed with care and tested for consistency—not manipulated for potency or marketed with illicit claims.

Shop Kratom With Verified Purity Standards

In today’s regulatory climate, companies can’t afford to rely on outdated or vague manufacturing systems. Super Speciosa’s investment in full-scope safety isn’t a branding gimmick—it’s a survival strategy. And one that’s working.

Why Transparency Is Now the Ultimate Kratom Differentiator

Transparency has become one of the most important differentiators in the modern supplement space—especially in industries like kratom, where federal regulations are still evolving and misinformation runs rampant. For consumers who are increasingly concerned with not just what they’re consuming but where it came from, how it was processed, and who is behind it, transparency is no longer optional. It’s the new standard.

Super Speciosa recognized this long before the 2025 regulatory wave. While other kratom brands focused on marketing hype or generic strain names, Super Speciosa focused on building a trackable, auditable, and honest product experience.

Every Super Speciosa product includes a lot number, which ties directly to a published Certificate of Analysis (COA) from an accredited third-party laboratory. These COAs aren’t hidden behind customer service logins or PDF requests. They are freely accessible on the website, allowing customers to verify:

  • Alkaloid content (mitragynine and trace 7-OH)
  • Heavy metal levels (lead, arsenic, cadmium, mercury)
  • Microbiological safety (E. coli, salmonella, mold, yeast)
  • Solvent and contaminant clearance

That level of data transparency is rare—not just in kratom, but across the entire supplement industry. Most companies don’t want customers seeing the test results behind the scenes, especially if they’re only testing intermittently or relying on supplier-provided certificates. Super Speciosa flips that model on its head by making transparency a selling point.

The company’s customer support staff is also trained to explain how these lab results work—what’s being measured, why the numbers matter, and how to interpret batch variation. This empowers customers to make data-driven buying decisions, instead of relying on strain color or anecdotal claims.

But transparency goes beyond lab tests. Super Speciosa publishes its entire manufacturing process in detail—from pasteurization to blending, to testing and packaging. It outlines its supply chain sourcing practices, explains its internal GMP audits, and documents how it qualifies every supplier and lab it works with. That kind of process-level openness isn’t typical in an industry where most companies still operate in secrecy or behind ambiguous product claims.

And in 2025, that strategy is paying off. As the FDA begins targeting products containing enhanced or synthetic 7-hydroxymitragynine—and as consumers grow wary of what’s real versus what’s manipulated—Super Speciosa’s commitment to full-spectrum transparency is becoming its most powerful marketing asset.

The brand isn’t trying to hide behind flashy product names, mysterious blends, or claims of “extra strength.” Instead, it leans into what it can prove: scientific documentation, third-party testing, and customer education. And as a result, it has earned trust not only from everyday consumers but also from regulatory watchdogs and advocacy groups.

In a climate where uncertainty surrounds many kratom vendors, Super Speciosa is building a different kind of relationship: one where customers know exactly what they’re buying, why it’s safe, and who’s behind it.

View Verified COAs and GMP Credentials at Super Speciosa

This kind of transparency isn’t just good business—it’s a reflection of how supplement companies should operate in the post-2025 era. In the long run, trust will win where flash cannot.

What to Look for When Buying Kratom Today

In this new enforcement era, choosing the right kratom product is about more than price or strain. It’s about verifying that the company behind it is legitimate, traceable, and prepared to survive growing scrutiny.

Here’s what to look for:

  • AKA GMP certification — the only nationally recognized standard for kratom vendors
  • Full lab reports per batch, not just “tested” claims
  • Ingredient traceability, with no synthetic or enhanced alkaloid content
  • Clear manufacturing SOPs, like pasteurization and blending

Super Speciosa checks all of these boxes—and publishes the data to prove it.

Visit the Official Super Speciosa Site

Final Thoughts: In a Time of Change, Choose Kratom with a Conscience

As public awareness of kratom continues to rise, so too does consumer confusion. With a wave of new brands entering the market, a patchwork of state-by-state regulations, and growing media attention around FDA enforcement, the average kratom buyer is left wondering: How do I know which products are safe? Which brands can I trust?

Unfortunately, the burden of due diligence often falls on the customer—especially in an industry still working toward consistent regulation. But there are reliable signals that separate responsible kratom companies from risky, short-term vendors.

The first—and most important—credential to look for is GMP certification from the American Kratom Association (AKA). The AKA’s Good Manufacturing Practices program is currently the only third-party system that verifies kratom companies are following clean, documented, and auditable production processes. Brands that earn this certification must undergo rigorous quality audits, standardize their production protocols, and demonstrate full product traceability from source to shelf.

Super Speciosa was one of the first companies to earn this GMP distinction, and it maintains active compliance by submitting to periodic inspections and keeping all SOPs current. That alone places it in the top tier of kratom vendors.

The second sign to look for is batch-level third-party lab testing. Many brands advertise that their kratom is “lab tested,” but fail to provide actual reports—or worse, they rely on outdated or supplier-submitted tests that don’t match the product you’re buying. A reputable brand will:

  • Test every single batch, not just a few
  • Partner with independent, ISO-certified laboratories
  • Share Certificates of Analysis (COAs) openly with customers
  • Include test results for alkaloids, microbial safety, and heavy metals

Super Speciosa checks all of these boxes. Every product sold is matched to a corresponding lab report, which customers can access by scanning the lot number on the package or visiting the brand’s website. That level of traceability is rare in any industry—let alone in one where many vendors operate anonymously.

Buyers should also evaluate ingredient integrity. In the wake of the FDA’s July 2025 enforcement against companies enhancing products with concentrated 7-hydroxymitragynine (7-OH), it’s more important than ever to avoid vendors who market “extra potent,” “fast-acting,” or “enhanced alkaloid” products without transparency. These buzzwords often signal chemical tampering or illegal formulation.

By contrast, Super Speciosa sells only natural kratom leaf formulations, meaning its products reflect the alkaloid profile as found in nature—without synthetics, isolates, or manipulated ratios. That’s key for both legality and safety.

Another important factor is customer service and education. Reputable brands invest in support teams that can explain how kratom works, what the lab reports mean, and how to choose a product based on need—not hype. Super Speciosa’s knowledge base, support staff, and customer communications reflect a clear understanding of kratom’s nuances and regulatory boundaries.

Finally, watch for sourcing transparency. Does the brand explain where its kratom comes from? Are farming and drying practices shared openly? Is there clarity about how the product was harvested, stored, and shipped?

Super Speciosa answers yes to all of the above. It works directly with trusted farms in Southeast Asia and controls its importation, pasteurization, blending, and packaging—all from its U.S.-based GMP facility.

Compare Kratom Vendors and See Why Super Speciosa Leads the Pack

In a market flooded with confusing options, these are the critical filters that help shoppers make smarter decisions. And as regulatory scrutiny increases, the brands that survive will be the ones that were already doing it right.

Kratom Buyer Trends in 2025: What Today’s Consumer Really Wants

The kratom landscape in 2025 looks very different than it did just a few years ago. What was once a niche herbal supplement primarily traded in underground forums and local smoke shops has become a mainstream wellness topic attracting everyone from health-conscious biohackers to consumers seeking natural alternatives to over-the-counter products.

But with the FDA’s recent enforcement against 7-hydroxymitragynine (7-OH) enhanced formulations, consumer behavior is shifting dramatically—and fast.

One of the biggest emerging trends? Safety-first kratom buying.

Consumers today are no longer just looking for “strong kratom” or the cheapest capsule. Instead, they’re Googling things like:

  • “Best kratom brands with lab testing”
  • “Where to buy GMP-certified kratom in the U.S.”
  • “Is kratom legal in my state?”
  • “Natural kratom vs synthetic kratom safety”
  • “Does Super Speciosa test for 7-OH?”

This signals a maturing market. Shoppers want confidence, not just potency. They’re more informed than ever, and they’re doing side-by-side brand comparisons, reading COAs, and asking questions that only the most transparent companies can answer.

Platforms like Reddit, YouTube, TikTok, and Quora are also accelerating this shift. Educational creators and kratom reviewers are highlighting the importance of verified lab results, batch traceability, and clean manufacturing practices. And on those metrics, Super Speciosa is consistently mentioned as a brand that checks every box.

Another key trend: shift from smoke shops to online DTC (direct-to-consumer) kratom brands. Consumers now prefer ordering from websites they trust—especially those that provide lab results, detailed product descriptions, and responsive customer service.

And finally, there’s a trend toward strain diversity and product form experimentation. While powders and capsules still dominate, kratom tea bags, tinctures, and even gummies are gaining ground. Super Speciosa’s relaunch of its Enhanced Watermelon Kratom Tincture tapped into this very trend—offering convenience, flavor, and dosage control in a format that appeals to modern consumers.

Browse Super Speciosa’s Trending Kratom Products

If 2023 was the “wild west” of kratom, and 2024 was the year of legal uncertainty, then 2025 is shaping up to be the year of consumer sophistication. And Super Speciosa is one of the few brands already built to meet the moment.

Inside the Super Speciosa Lab Testing Philosophy

Lab testing isn’t just a marketing buzzword at Super Speciosa — it’s a scientific and ethical foundation that supports the entire brand. In an industry flooded with unverified claims and product inconsistencies, Super Speciosa’s lab testing philosophy acts as both a shield for the consumer and a standard for the company’s internal integrity.

Where many kratom companies view lab testing as a periodic checkpoint or a one-off box to tick, Super Speciosa treats it as a non-negotiable production step. Every single batch of kratom is tested before it is approved for sale, and not just once — testing is performed at multiple stages during the production cycle to verify consistency and eliminate risk.

The company uses third-party, ISO-17025 accredited laboratories, which means results are generated under strict international quality standards, with validated methods and repeatable results. These aren’t casual quick-scan tests or in-house rapid reads — they’re full Certificates of Analysis (COAs) generated by professional labs with no affiliation to the manufacturer.

Each COA is publicly available and maps exactly to the lot number printed on the customer’s packaging — ensuring a one-to-one verification trail. This allows Super Speciosa to deliver something very few supplement companies offer: end-to-end consumer visibility into the safety, identity, and potency of every product sold.

What exactly do these labs test for?

  1. Alkaloid Profile: Mitragynine and 7-hydroxymitragynine (7-OH) are measured to ensure the product contains only the naturally occurring ratios found in raw kratom leaf. Super Speciosa does not spike, isolate, or boost these alkaloids. Testing confirms that 7-OH remains at trace levels — naturally present and legally compliant.
  2. Microbial Contaminants: Kratom, as a raw botanical, is susceptible to pathogens like E. coli, Salmonella, mold, and yeast. Super Speciosa’s pasteurization process addresses this risk, and microbial testing confirms it was successful. COAs report total aerobic count, total coliforms, and specific pathogens.
  3. Heavy Metals: Because kratom is grown in soil — often in tropical regions with varying mineral content — testing for heavy metals like arsenic, cadmium, lead, and mercury is essential. Super Speciosa adheres to NSF-style limits on all toxic metals and will reject any batch that exceeds even one threshold.
  4. Residual Solvents & Adulterants: Although Super Speciosa doesn’t use solvent-based extraction, it tests for residual compounds anyway. This is especially important for consumers concerned about unethical manufacturing practices.
  5. Visual Identity & Purity Checks: Labs confirm that each batch is what it claims to be — no fillers, binders, or substitute plants.

By publishing this data and encouraging customers to review their COAs, Super Speciosa creates a culture of accountability and customer empowerment. Shoppers no longer need to trust blindly — they can verify every claim themselves.

Access Super Speciosa’s Lab Reports by Batch

In a time when the FDA is cracking down on adulterated kratom and vague product formulations, Super Speciosa’s lab testing transparency has become a competitive moat. It’s not just about safety — it’s about education, legitimacy, and long-term brand trust.

Contact & Company Information

  • Brand Name: Super Speciosa
  • Website: https://superspeciosa.com
  • Email: info@superspeciosa.com
  • Location: Jacksonville, FL, United States
  • Customer Support Hours: 9am–5pm EST
  • AKA GMP Qualified Vendor: Yes

Disclaimer

This release is for informational purposes only. No statements herein have been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult a healthcare professional before using any supplement.


            



Source link

31 07, 2025

Ethereum’s Low Funding Rates Signal ‘Full-Fledged’ Rally Ahead: Analyst

By |2025-07-31T23:42:27+03:00July 31, 2025|Crypto News, News|0 Comments

Ethereum’s ten-year milestone has been marked not just by reflection but by a steady rally that has investors bracing for what could be the cryptocurrency’s next big breakout.

With ETH trading at $3,800 at press time, still 24% below its all-time high, pseudonymous CryptoQuant analyst CoinCare says its subdued futures funding rates and deep-pocketed accumulation suggest the uptick is far from over.

Source link

31 07, 2025

Ethereum Torch NFT Mints 780000 Units in 10 Days Showcasing Community Engagement

By |2025-07-31T21:51:55+03:00July 31, 2025|News, NFT News|0 Comments


The Ethereum Torch NFT, launched to commemorate Ethereum’s 10th anniversary, concluded its minting phase with a record-breaking 780,000 NFTs minted across more than 660,000 unique Ethereum wallet addresses [1]. The project, which ran for 10 days, offered participants a symbolic and interactive way to engage with Ethereum’s history by “passing the torch” from one wallet to another, visually representing the network’s decentralized and community-driven ethos [1]. The initiative succeeded in fostering broad participation due to its low entry barrier—essentially free to mint, aside from minimal gas fees—and its social, interactive mechanism [1].

The success of the Ethereum Torch NFT is a reflection of the strong and diverse engagement from the Ethereum community, far beyond traditional NFT collectors. The sheer scale of participation highlights the accessibility and inclusivity of the event, demonstrating that the Ethereum network can support a high volume of transactions without significant congestion [1]. This also underscores the robustness of the Ethereum infrastructure and its ability to facilitate community-driven digital initiatives on a large scale [1].

A unique aspect of the Ethereum Torch NFT is its planned obsolescence. On July 30, all minted NFTs will be burned—sent to an unspendable blockchain address—effectively removing them from circulation. This action, while finalizing the commemorative period, also emphasizes the symbolic nature of the event. The burn marks the conclusion of the relay-like celebration, reinforcing the idea that the NFT’s value lies not in its tradability but in its role as a shared digital artifact [1]. The transaction history of each NFT will remain on the blockchain, serving as a permanent record of individual participation [1].

The Ethereum Torch NFT has set a precedent for future digital commemorations in the blockchain space. It demonstrates that the value of NFTs can extend beyond monetary speculation and into community-building, historical documentation, and interactive storytelling [1]. The project reaffirms Ethereum’s position as a dynamic and innovative blockchain platform, capable of fostering widespread engagement through creative digital experiences [1]. It also highlights the potential for future NFT projects to prioritize accessibility and communal engagement over profit, opening new avenues for creative and educational uses of blockchain technology [1].

The Ethereum Torch NFT’s legacy will be preserved through the blockchain’s immutable record, ensuring that the event remains a part of Ethereum’s history even after the NFTs themselves are removed from circulation [1]. The 780,000 participants, now part of a shared digital narrative, have contributed to a unique chapter in Ethereum’s journey, illustrating the power of collective participation in shaping the future of decentralized systems [1].

[1] https://coinmarketcap.com/community/articles/688b9ead975515507af33498/



Source link

31 07, 2025

Natural Gas and Oil Forecast: Sanction Delay Cools Rally, Crude Risks Deeper Pullback

By |2025-07-31T21:50:44+03:00July 31, 2025|Forex News, News|0 Comments


Scan QR code to install app

Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party’s services, and does not assume responsibility for your use of any such third party’s website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.Risk DisclaimersThis website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.



Source link

31 07, 2025

Looks to build on strength above 200-day SMA post-BoJ, ahead of US PCE data

By |2025-07-31T21:49:42+03:00July 31, 2025|Forex News, News|0 Comments

  • USD/JPY reverses an intraday dip led by upbeat data from Japan and the BoJ’s hawkish pause.
  • The uncertainty over the timing of the next BoJ interest rate hike continues to undermine the JPY.
  • Reduced bets for a September rate cut by the Fed act as a tailwind for the USD and spot prices.

The USD/JPY pair attracted fresh buyers following an intraday slide to the 148.60-148.55 region and touched its highest level since early April during the first half of the European session on Thursday. The Japanese Yen (JPY) struggles to capitalize on its gains, led by the upbeat domestic macro data and the Bank of Japan’s (BoJ) hawkish pause. This, along with the underlying US Dollar (USD) bullish sentiment, turns out to be a key factors acting as a tailwind for the currency pair.

A preliminary government report showed that Industrial Production in Japan unexpectedly rose 1.7% from the previous month in June, signaling resilience among manufacturers despite headwinds from US trade tariffs. A separate report revealed that Retail Sales in Japan grew for the 39th consecutive month, by 2.0% year-on-year in June, compared to the previous month’s downwardly revised reading of 1.9% and better than market expectations. The latter suggested that private consumption in Japan remained strong, which, along with the US-Japan trade deal, keeps hopes alive for the BoJ rate hike later this year.

In fact, BoJ Governor Kazuo Ueda, speaking to reporters during the post-meeting press conference, said that Japan’s economy is recovering moderately and that the US-Japan trade deal reduces uncertainty over the economic outlook. Earlier, the central bank, as was expected, decided to maintain the status quo at the end of the July meeting. In the accompanying policy statement, the BoJ reiterated that it will continue to raise the policy rate if the economy and prices move in line with the forecast. Adding to this, an upward revision of the BoJ’s inflation forecast revived bets for a further monetary policy tightening by the year-end.

The initial market reaction, however, turns out to be limited amid the growing acceptance that signs of cooling inflation in Japan and political uncertainty would complicate the BoJ’s policy normalization path. The ruling Liberal Democratic Party’s loss in the July 20 polls fueled concerns about Japan’s fiscal health amid calls from the opposition to boost spending and cut taxes. This suggests that prospects for BoJ rate hikes could be delayed for a bit longer. Meanwhile, the Federal Reserve (Fed) Chair Jerome Powell tempered hopes for an immediate rate cut, which favours the USD bulls and supports the USD/JPY pair.

In fact, Powell said it was too soon to say whether the Fed would cut rates at its next meeting and that the current modestly restrictive monetary policy has not been holding back the economy. Earlier on Wednesday, the US central bank left interest rates unchanged in a split decision that saw two governors dissenting for the first time since 1993. The market focus now shifts to the release of the US Personal Consumption Expenditure (PCE) Price Index later during the North American session. The crucial inflation data will influence the USD and produce short-term trading opportunities around the USD/JPY pair.

USD/JPY daily chart

Technical Outlook

The USD/JPY pair is now looking to build on the momentum beyond the 200-day Simple Moving Average (SMA) and could aim to reclaim the 150.00 psychological mark amid positive oscillators on the daily chart. The momentum could extend further towards the next relevant hurdle near the 150.40 area before spot prices eventually climb to the 151.00 round figure.

On the flip side, the 149.00 mark now seems to protect the immediate downside. Any further corrective slide might continue to attract dip-buyers and find decent support near the 148.55 region. A convincing break below the latter, however, could drag the USD/JPY pair to the 148.00 mark and the overnight swing low, around the 147.80 area. Some follow-through selling would expose the 147.00 mark and the 100-day SMA, currently pegged near the 146.70 region. The latter coincides with last week’s swing low, which, if broken, might shift the near-term bias in favor of bearish traders.

Source link

31 07, 2025

4 Portland matcha cafes you need to try this summer

By |2025-07-31T21:43:52+03:00July 31, 2025|Dietary Supplements News, News|0 Comments


A raspberry vanilla matcha, banana cream matcha and strawberry matcha from Project Matcha in Northeast Portland. Vickie Connor/The Oregonian

Portland is abuzz with coffee shops, but the drink of the summer might lean greener.

Matcha — a finely ground, vibrant green powder made from tea leaves grown primarily in Japan — is the it girl of Instagram beverages. Maybe you’ve watched an influencer give a tutorial on how to hand-whisk your own matcha at home or seen a group of green-tea fanatics scrutinize the exact shade of their lattes.

If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other third-party partners in accordance with our Privacy Policy.



Source link

31 07, 2025

Wrapped XRP on Ethereum Soars to Record High Amid DeFi and Cross-Chain Boom

By |2025-07-31T21:40:55+03:00July 31, 2025|Crypto News, News|0 Comments

Delving Deeper into Wrapped XRP on Ethereum

Wrapped XRP on Ethereum has soared past $60 million in market cap, marking a new all-time high and highlighting surging demand for cross-chain utility and DeFi integration.

WXRP, backed 1:1 by XRP in custody, gives holders seamless access to Ethereum’s DeFi ecosystem.

What’s Driving the Uptick?

Rising DeFi demand for wrapped tokens is key, as users increasingly leverage WXRP to lend, borrow, or provide liquidity on Ethereum-based protocols. Serving as a crucial bridge between the XRP Ledger and Ethereum, WXRP enables seamless cross-chain integration and utility.

Secondly, Cross-chain integration is accelerating in 2025, with growing institutional interest in multi-chain solutions over single-chain silos. The rise of wrapped assets like WXRP reflects this shift, enabling seamless asset flow across blockchains and powering the interoperable future of crypto.

Thirdly, XRP itself has seen extraordinary relative gains up by 552% year‑on‑year since July 2024 and 49% year‑to‑date through late July 2025. Elevated whale accumulation and bullish technical formations on XRP’s native ledger have bolstered confidence in XRP’s long‑run utility.

Why It Matters

  • DeFi Access: WXRP enables XRP holders to tap Ethereum’s DeFi ecosystem through staking, yield farming, or collateralized lending, unlocking new utility for XRP beyond payments.

  • Cross‑Chain Trust: Surpassing $60 million signals growing trust in wrapped collateral and custodial reliability, which is important for institutions or retail users bridging assets.

  • Ecosystem Synergy: This milestone may presage deeper integrations between the XRP Ledger ecosystem and Ethereum’s protocols, accelerating innovation in both networks.

As Ethereum continues its institutional-strength bullish run now trading at around $3,800 with derivatives open interest surpassing $60 billion, WXRP momentum may further grow. 

DeFi participants may increasingly include wrapped XRP in portfolios or liquidity strategies, especially given that XRP recently hit a new all-time high of $3.65. 

XRP’s Bullish Flag Plays Out

According to market analyst Lingrid, XRP recently broke key resistance with a strong breakout and is now consolidating just below the upper range. The price continues to hold within a bullish flag, signaling a healthy correction after a sharp upward impulse.

She added, “If the current pullback holds above the diagonal support, a renewed push toward 3.60–3.70 becomes likely. Bulls remain in control as structure supports further upside.”

At the time of this writing, XRP was trading at the psychological price of $3.10 amid intensified consolidation.

Conclusion

WXRP’s market‑cap breakthrough is a meaningful indicator of growing demand for cross‑chain liquidity, interoperability, and DeFi usage of XRP. 

As wrapped assets mature, this milestone may mark the beginning of deeper integration between XRP and Ethereum ecosystems, offering fresh opportunities for holders, developers, and decentralized finance at large.

As the value of WXRP skyrockets, it remains to be seen how XRP’s price plays out in the short term as heightened consolidation takes center stage. 

Source link

31 07, 2025

Facts About DCIS – HealthyWomen

By |2025-07-31T21:32:28+03:00July 31, 2025|Fitness News, News|0 Comments

Ductal carcinoma in situ (DCIS) is a very early form of breast cancer that makes up about 1 out 5 cases of breast cancer.

While any cancer diagnosis is scary, DCIS is noninvasive and very treatable. With appropriate treatment and follow-up care, the outlook is excellent. And the five-year survival rate for people diagnosed with DCIS is 98%.

What is DCIS?

DCIS is the earliest stage of breast cancer, sometimes called stage 0 breast cancer.

The name ductal carcinoma in situ is a bit confusing. Here’s what it means:

  • Ductal: The cancer is in the cells lining the milk ducts. It might be in one or both breasts.
  • Carcinoma: These ductal cells become abnormal (cancerous).
  • In situ: The cancer stays “on site” where it started. It might spread to more ductal cells, but it does not spread to other areas.

DCIS is noninvasive, meaning it has not spread from where it started, but it still needs to be treated. Although DCIS itself has a great prognosis, research does show that people diagnosed with DCIS have a higher risk of developing invasive cancer later. Anywhere from 20 to 50% of DCIS cases might be a precursor to a higher stage of breast cancer.

Healthcare providers can’t tell which cases will progress. So the safest approach is to treat all cases of DCIS quickly. Treating DCIS intensively leads to better outcomes and lowers the risk of invasive cancer down the road.

Symptoms and diagnosis of DCIS

DCIS usually doesn’t cause any noticeable symptoms. Some people might notice a lump in their breast, skin irritation or itchiness, a sore or discharge from the nipple. But this isn’t common. Most of the time, DCIS is caught by a mammogram — those regular screenings are important!

If you have DCIS, the mammogram might show microcalcification clusters. These clusters are calcium deposits in the breast. They might be there for many reasons. In fact, they’re pretty common in women over 50. However, certain patterns of microcalcifications can indicate an early stage of cancer. So, if these are spotted on your mammogram, you’ll need more imaging done.

If you have signs of DCIS, your healthcare provider (HCP) may request one or more of the following:

  • Diagnostic mammogram: Provides more detailed X-ray images of the breast than a screening mammogram, often from different angles or positions.
  • Ultrasound: Uses sound waves to get images of the breast tissue. Sometimes an ultrasound is used to guide a biopsy.
  • Breast MRI: Magnetic resonance imaging is more sensitive than a mammogram or an ultrasound.

After imaging, the next step is a biopsy: a small piece of tissue is taken from the breast, then analyzed by a pathologist. The analysis determines what kind of DCIS is present and the best course of treatment.

Different types of DCIS

DCIS is categorized by something called nuclear grade. This scale “grades” or compares how the cancer cells look in comparison with normal breast cells. The cells might be low, intermediate, or high grade. A higher grade means the cancer cells are more abnormal and fast-growing.

It’s also important to determine the hormonal makeup of the cancerous cells. This helps doctors decide on the best treatment approach. Some cancer cells have hormone receptors for estrogen or progesterone, or both. Having these receptors is favorable. It means the cancer grows more slowly and depends on hormones to survive. Most cases of DCIS are hormone-receptor positive.

How is DCIS treated?

Treatment for DCIS is usually straightforward: surgery, often followed by radiation therapy. The radiation ensures that all cancerous cells are removed. In some cases, hormone therapy may be recommended. Chemotherapy is not used to treat DCIS.

Surgery

A lumpectomy is also called a partial mastectomy or breast-saving surgery. The surgeon removes tissue from the breast. The tissue includes the cancerous cells and some healthy tissue around the area. The breast itself is not removed.

A mastectomy is a surgery that removes all tissue, or the entire breast. Patients might opt to have breast reconstruction surgery after a mastectomy.

Which surgery is needed depends on the DCIS spread. If the cancer is in a small, contained area, a lumpectomy is usually possible. If the cancer hasis spread out or scattered through the ductal cells, a mastectomy will be needed.

Radiation therapy

Radiation therapy uses high-energy beams, usually X-rays, to kill cancer cells that were not removed during surgery. It’s associated with a lower risk of recurrence.

Hormone therapy

If the cancer cells have hormone receptors, your healthcare provider might recommend hormone therapy to help prevent recurrence. If you have a mastectomy, hormone therapy is usually not needed.

Does DCIS recur?

While DCIS can come back, its recurrence rate is low. For people who have a lumpectomy followed by radiation therapy, it’s less than 15%.

The DCIS grade also has an effect on the recurrence rate. A lower grade equals a lower risk of recurrence. However, the risk of recurrence is higher for Black women than for Asian, Hispanic, or white women. That may be because white women benefit from more follow-up imaging surveillance. These systemic racial/ethnic disparities have fatal consequences: the rate of breast cancer mortality after DCIS is higher for Black women.

Read: Why Do Women of Color Have Worst Breast Cancer Outcomes? >>

Regular mammograms help catch DCIS so it can be treated quickly. After treatment for DCIS is complete, regular screenings help spot any abnormalities. With good follow-up, you’ve got everything on your side to stay healthy after a DCIS diagnosis.

This educational resource was created with support from Merck.

From Your Site Articles

Related Articles Around the Web



Source link

31 07, 2025

Injective Tokenizes SharpLink Shares in DeFi Expansion Move

By |2025-07-31T19:49:24+03:00July 31, 2025|News, NFT News|0 Comments


Injective, a Layer 1 blockchain platform, has announced the tokenization of shares in SharpLink, a prominent Ethereum treasury company, marking a significant step in the evolution of tokenized assets [1]. This initiative, described as the first “Digital Asset Treasury” (DAT), brings SharpLink’s publicly traded stock SBET onto Injective’s blockchain via the iAssets framework, a novel system that enables native programmability and cross-protocol compatibility for traditional assets [1].

The move allows SBET holders to interact with their shares in a more dynamic way, including use as collateral, in derivatives, and within structured financial products. By transforming a static corporate Ether reserve into a yield-bearing on-chain asset, Injective aims to expand the functionality of traditional financial instruments within decentralized finance [1]. The SBET DAT also introduces governance hooks and integrated liquidity, enabling seamless integration across lending markets and other DeFi protocols.

SharpLink, which holds approximately 360,807 ETH valued at around $1.3 billion, has been a key player in the Ethereum treasury space. The firm has attracted significant interest in its ETH acquisition and staking strategy, particularly following its collaboration with Consensys employees [1]. While it lags behind BitMine in terms of ETH holdings, SharpLink remains one of the most actively managed treasury firms in the sector. However, over the past 24 hours, SBET shares have traded down over 12%, currently valued at $22.63 with a market cap of $2.6 billion [1].

Injective’s tokenization of SBET shares aligns with broader trends in the crypto market, including the tokenization of equities by platforms like Robinhood and Kraken, as well as the rising interest in corporate crypto treasuries [1]. The platform, backed by Binance, Jump Crypto, and Pantera Capital, has been expanding its capabilities through cross-chain EVM support and on-chain trading features for spot, futures, and options.

The announcement follows recent regulatory developments, including Canary Capital’s ETF filing for INJ, Injective’s native token. INJ currently trades around $13.91, having reached a peak of $52.62 in March 2024 [1]. The tokenization of SharpLink shares could further solidify Injective’s position as a leader in tokenized finance, offering real-world asset exposure through a decentralized framework.

As tokenization continues to gain traction, platforms like Injective are redefining the boundaries of asset ownership and investment. By enabling traditional financial instruments to operate within a blockchain environment, the initiative reflects a growing convergence between conventional finance and decentralized ecosystems [1].

Sources:

[1] Mirza – X

https://x.com/mirza

[2] Joseph Chalom joins SharpLink Gaming as co-CEO, jumps

https://cryptorank.io/news/feed/2d601-sharplink-gaming-joseph-chalom-as-co-ceo

[3] Altcoins News, Latest Stories & Analysis

https://invezz.com/news/cryptocurrency/altcoins/



Source link

31 07, 2025

Natural gas price repeats the critical support– Forecast today – 31-7-2025

By |2025-07-31T19:48:27+03:00July 31, 2025|Forex News, News|0 Comments


Natural gas price returned to form new negative trading affected by stochastic negativity, providing strong pressures on the critical support at $3.050, which represents the head and shoulders pattern.

 

Note that breaking the current support will confirm activating the negative pattern, to move to a new negative track, forcing it to suffer several losses by reaching $2.710 and $2.390, for regaining the bullish bias we recommend waiting for providing positive close above $3.320 to ease achieving several gains that might begin at $3.450 and $3.610.

 

The expected trading range for today is between $2.710 and $3.150.

 

Trend forecast: Bearish





Source link

Go to Top